Ascidian Therapeutics’ technology edits RNA to treat inherited disorders. While the startup’s lead internal program is for the retinal disorder Stargardt disease, its new R&D alliance with Roche will focus on developing RNA-editing therapies for neurological indications.
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Ascidian Therapeutics is developing therapies for inherited disorders that work by editing RNA with an approach that could offer advantages over currently available genetic medicines. The biotech’s lead program is in preclinical development for Stargardt disease, a rare eye disorder caused by multiple genetic mutations.